A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

Herbert I. Hurwitz, Louis Fehrenbacher, William Novotny et al. · New England Journal of Medicine · 2004 · 11K citations · Full text

Medicine, Oncology, Pharmacology +15

Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer

Michael S. Gordon, Kim Margolin, Moshe Talpaz et al. · Journal of Clinical Oncology · 2001 · 919 citations

Medicine, Oncology, Pharmacology +17

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

Dana D. Hu‐Lowe, Helen Y. Zou, Maren L. Grazzini et al. · Clinical Cancer Research · 2008 · 628 citations

Medicine, Oncology, Pharmacology +17

Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study

Ezra E.W. Cohen, Lee S. Rosen, Everett E. Vokes et al. · Journal of Clinical Oncology · 2008 · 622 citations · Full text

Medicine, Oncology, Pharmacology +14

Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.

E Gupta, Timothy M. Lestingi, Rosemarie Mick et al. · PubMed · 1994 · 506 citations

Pharmacy, Pharmacokinetics, Pharmacology +14